Shuttle Pharmaceuticals Holdings, Inc. — Q1 2024 Form 10-Q Summary
Business Context and Reporting Period
Shuttle Pharmaceuticals is a development-stage biotechnology company focused on cancer therapies, including Ropidoxuridine for use with radiation therapy and a pipeline of HDAC inhibitors. The unaudited interim report covers the three months ended March 31, 2024. The company has no commercial revenue and remains dependent on financing, grants, and successful clinical development.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 / Prior Period |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1.385 million | $1.545 million |
| Loss from operations | $1.385 million | $1.545 million |
| Net loss | $1.731 million | $975 thousand |
| Net loss per share | $0.10 | $0.07 |
| Cash used in operating activities | $1.239 million | $1.338 million |
| Cash and cash equivalents at period end | $1.399 million | $7.169 million at March 31, 2023 |
| Marketable securities | $2.789 million | $2.887 million at December 31, 2023 |
| Working capital | $2.922 million | $4.551 million at December 31, 2023 |
| Total liabilities | $1.992 million | $1.896 million at December 31, 2023 |
| Net convertible note carrying value | $941 thousand | $731 thousand total current and non-current at December 31, 2023 |
R&D expense declined 36% to $586 thousand, primarily because drug-product manufacturing had been completed and clinical-trial activity was awaiting initiation. General and administrative expense increased 27% to $325 thousand, and legal and professional expense increased 29% to $474 thousand.
Other expense was $346 thousand, compared with other income of $570 thousand in the prior-year quarter. Q1 2024 included $498 thousand of interest expense, including $446 thousand of debt-discount amortization, a $71 thousand loss on convertible-debt settlement, and a $198 thousand non-cash gain from changes in derivative liabilities.
Cash declined by $1.178 million during the quarter. Investing activities provided $101 thousand, primarily from $120 thousand of marketable-securities proceeds, while financing activities used $40 thousand. The company issued 625,573 shares to settle $235 thousand of principal and $19 thousand of accrued interest on its convertible note and issued 125,000 shares upon vesting of restricted stock units.
Material Changes Versus the Prior Comparable Period
- Net loss increased by $756 thousand, or 78%, despite a $160 thousand, or 10%, reduction in operating expenses.
- The prior period benefited from a $1.241 million derivative-liability fair-value gain; the comparable Q1 2024 gain was $198 thousand.
- Interest expense decreased 17% to $498 thousand, and no finance fee or related-party interest expense was recorded in Q1 2024.
- R&D spending decreased by $336 thousand, while general and administrative and legal and professional expenses increased by $69 thousand and $107 thousand, respectively.
- Cash and cash equivalents decreased 46% from December 31, 2023, and working capital decreased 36% to $2.9 million.
- Current liabilities increased 43% from year-end, primarily due to the current portion of the convertible note and accrued interest.
- The company corrected an immaterial prior-period classification error that shifted $89 thousand from R&D expense to general and administrative expense for Q1 2023; management stated that the correction did not affect net loss, earnings per share, working capital, or cash flow.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management stated that the company remained on track to commence its Phase II Ropidoxuridine study in the second quarter of 2024 after incorporating FDA-recommended trial expansion changes and obtaining central IRB approval.
- The company disclosed substantial doubt about its ability to continue as a going concern within one year after issuance of the financial statements. Existing cash, marketable securities, and prior financing are not expected to fund operations and clinical trials for the next 12 months.
- Management was initiating a $4.5 million rights offering and had applied for an NIH SBIR grant. The rights offering was not yet effective, and its completion and funding were not assured.
- Under a February 2024 purchase agreement, SRO, LLC committed to purchase $2.25 million of units and could backstop up to an additional $2.25 million if the full rights offering was not subscribed. The offering was subject to conditions, including effectiveness of the registration statement; if the full $4.5 million was not raised, the transaction could fail and escrowed funds could be returned.
- The Alto convertible note had $2.020 million of outstanding principal at March 31, 2024, a stated 5% interest rate, an approximately 244% effective interest rate, monthly amortization requirements, conversion features, covenants, and a March 2025 maturity that may be extended by the noteholder. The lender has security interests in the company’s assets and intellectual property.
- Outstanding warrants totaled 1,446,155 shares, with a weighted-average exercise price of $2.74. The company also had 2,578,438 anti-dilutive common-stock equivalents from convertible notes, warrants, and RSUs.
- Management reported ineffective disclosure controls and material weaknesses in accounting policies for complex transactions, segregation and review procedures, expense classification, and information-technology general controls.
- Following an SEC order against former auditor BF Borgers in May 2024, the company stated that its 2022 financial statements would need to be re-audited by a licensed PCAOB accounting firm to support the planned rights-offering registration statement.
- The company reported no pending or threatened legal proceedings that it believes would have a material adverse effect.
Investor Verification Priorities
- Verify whether the $4.5 million rights offering became effective, closed, and generated sufficient proceeds, including the status of the SRO commitment and backstop.
- Assess near-term liquidity against the $1.2 million quarterly operating cash burn, convertible-note payment requirements, lease obligations, and clinical-trial funding needs.
- Review the Alto note’s conversion, acceleration, covenant, security, and potential dilution provisions, including the approximately 244% effective interest rate.
- Confirm the timing and successful commencement of the Phase II Ropidoxuridine trial and the financial impact of the FDA-recommended expansion.
- Monitor the re-audit of the 2022 financial statements and any effects on the rights offering or SEC filings.
- Evaluate remediation of the disclosed material weaknesses and the reliability of future financial reporting.